Virtus LifeSci Biotech Clinical Trials ETF
10 hedge funds and large institutions have $8.4M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Holders
10
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$517K | |
| 2 | +$68.9K | |
| 3 | +$60.6K | |
| 4 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
+$18.5K |
| 5 |
AWM
Avior Wealth Management
Omaha,
Nebraska
|
+$15K |
Top Sellers
| 1 | -$818K | |
| 2 | -$290K | |
| 3 | -$224K | |
| 4 |
Goldman Sachs
New York
|
-$37.9K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$18K |